Aviir company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aviir.com

Total Raised

$65.19M

Investors Count

7

Deal Terms

6

Aviir Funding, Aviir Valuation & Aviir Revenue

12 Fundings

Aviir's latest funding round was a Series D - III for $10M on June 21, 2013.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

6/21/2013

Series D - III

$10M

0

FY undefined

1

2/12/2013

Series D - II

$10M

0

FY undefined

5

9/19/2012

Debt - II

$5M

0

FY undefined

1

9/19/2012

Line of Credit

$99M

0

FY undefined

10

12/20/2011

Series D

$99M

0

FY undefined

10

Date

6/21/2013

2/12/2013

9/19/2012

9/19/2012

12/20/2011

Round

Series D - III

Series D - II

Debt - II

Line of Credit

Series D

Amount

$10M

$10M

$5M

$99M

$99M

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

5

1

10

10

Aviir Deal Terms

6 Deal Terms

Aviir's deal structure is available for 6 funding rounds, including their Series D - III from June 21, 2013.

Round

Series D - III

Series D - II

Series D

Debt

Series C

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

$99M

$99M

Dividend Rate

$99M

$99M

$99M

$99M

Liquidation Preferences

$99M

$99M

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

$99M

$99M

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series D - III

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series D - II

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Debt

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

Aviir Investors

7 Investors

Aviir has 7 investors. Bay City Capital invested in Aviir's Series D - III funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

3/12/2008

6/21/2013

7
Series B, Series C (2009), Series C - II (2009), Series C - III (2010), Series D (2011), Series D - II (2013), Series D - III (2013)

Venture Capital

California

00/00/0000

00/00/0000

New Leaf Venture Partners

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

Aberdare Ventures

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Merck Global Health Innovation Fund

Subscribe to see more

Corporate Venture

Pennsylvania

00/00/0000

00/00/0000

Partners & Partners

Subscribe to see more

First funding

3/12/2008

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

6/21/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

New Leaf Venture Partners

Aberdare Ventures

Merck Global Health Innovation Fund

Partners & Partners

Rounds

7
Series B, Series C (2009), Series C - II (2009), Series C - III (2010), Series D (2011), Series D - II (2013), Series D - III (2013)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Venture Capital

Corporate Venture

Location

California

New York

California

Pennsylvania

You May Also Like

G
Genera Biosystems

Genera Biosystems is a development phase company that designs, develops and produces and clinically effective human molecular diagnostics with a focus on women's health.

H
Helix Diagnostics

Helix Diagnostics LLC is pursuing development and commercialization of multiplexed DNA detection systems based on capillary electrophoresis.

M
MicroPhage

MicroPhage's mission is to be a worldwide pioneer in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility/resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics.

I
Integrative Diagnostics

Integrative Diagnostics is a early cancer detection company founded by Leroy Hood.

3
3PrimiR

3PrimiR is researching how mutations in micro RNA molecules can be used in cancer diagnostics.

C
Columbia BioSystems

Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.